SE512655C2 - Medication for infusion treatment - Google Patents
Medication for infusion treatmentInfo
- Publication number
- SE512655C2 SE512655C2 SE9303787A SE9303787A SE512655C2 SE 512655 C2 SE512655 C2 SE 512655C2 SE 9303787 A SE9303787 A SE 9303787A SE 9303787 A SE9303787 A SE 9303787A SE 512655 C2 SE512655 C2 SE 512655C2
- Authority
- SE
- Sweden
- Prior art keywords
- medication
- soln
- infusion
- solution
- durability
- Prior art date
Links
- 238000001802 infusion Methods 0.000 title abstract description 4
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 9
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000001419 dependent effect Effects 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000003978 infusion fluid Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 4
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 abstract 1
- 235000010262 sodium metabisulphite Nutrition 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Medication comprises an infusion soln. with L-dopa dissolved in hydrochloric acid and buffered with Addex-THAM to a degree of acidity so that the soln. maintains its properties, is tissue-tolerable and maintainable for periods permitting its use in clinical practice. The pH of the medication is 4.0-6.0 and sodium pyrosulphite is used to stabilise the soln. and improve its durability. The durability is pH-dependent and at pH 4.5 is 3 days.
Description
512 655 BESKRIVNING Stamlösning L-dopa 50 mg/ml Levodopum 5 g HCL 1 mol/131 g Natfii pyrosulfis 0.5 g Aqua ad injectabila ad 100 ml Lös upp levodopa i saltsyrai en 100 ml kolv. 512 655 DESCRIPTION Stock solution L-dopa 50 mg / ml Levodopum 5 g HCL 1 mol / 131 g Nat fi i pyrosul g s 0.5 g Aqua ad injectable ad 100 ml Dissolve levodopa in hydrochloric acid in a 100 ml flask.
Väg upp natriumpyrosulflt i en 10 ml injektionsflaska och tillsätt 2 ml sterilt vatten för upplösning.Weigh sodium pyrosul in a 10 ml syringe and add 2 ml of sterile water for dissolution.
Tillsätt 50 ml vatten till kolven med levodopa.Add 50 ml of water to the flask with levodopa.
Tillsätt natriumpyrosulfitlösningen. Lösningen blir klar och ljusgul.Add the sodium pyrosul solution. The solution becomes clear and light yellow.
Häll över i 100 ml mätkolv och fyll på vatten till märket.Pour into a 100 ml graduated flask and add water to the mark.
Sterilfiltrera ned i en 100 ml injektionsflaska. Använd Sterivex GV-filter 0.22 pm.Sterile filter into a 100 ml syringe box. Use Sterivex GV filter 0.22 pm.
L-dopa 5 mg/ml - infusionsvätska Levodopum 50 mg/ml (stamlösning) 20 ml Addex-Tham 2ml Glucos 50 mg/ml ad 200 ml Använd Glucos 50 mg/ml infusionsvätska 200 ml flaska.L-dopa 5 mg / ml - infusion solution Levodopum 50 mg / ml (stock solution) 20 ml Addex-Tham 2ml Glucos 50 mg / ml ad 200 ml Use Glucos 50 mg / ml solution for infusion 200 ml fl ash.
Sug ur uträknad mängd (enligt ovanstående exempel 22 ml) Glucos ur flaskan.Suck the calculated amount (according to the above example 22 ml) of glucose from the bottle.
Tillsätt Levodopa stamlösning i uträknad mängd (20 ml).Add Levodopa stock solution in calculated amount (20 ml).
Tillsätt Addex-Tham (2ml), pH ligger då mellan 4 och 6.Add Addex-Tham (2ml), the pH is then between 4 and 6.
Ljusskydda under förvaring och infusion.Light protection during storage and infusion.
Hållbarhet 3 dygn.Shelf life 3 days.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9303787A SE512655C2 (en) | 1993-11-17 | 1993-11-17 | Medication for infusion treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9303787A SE512655C2 (en) | 1993-11-17 | 1993-11-17 | Medication for infusion treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9303787D0 SE9303787D0 (en) | 1993-11-17 |
| SE9303787L SE9303787L (en) | 1995-05-18 |
| SE512655C2 true SE512655C2 (en) | 2000-04-17 |
Family
ID=20391770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9303787A SE512655C2 (en) | 1993-11-17 | 1993-11-17 | Medication for infusion treatment |
Country Status (1)
| Country | Link |
|---|---|
| SE (1) | SE512655C2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006006929A1 (en) | 2004-07-12 | 2006-01-19 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| WO2018224501A1 (en) | 2017-06-05 | 2018-12-13 | Dizlin Pharmaceuticals Ab | Levodopa infusion solution |
-
1993
- 1993-11-17 SE SE9303787A patent/SE512655C2/en not_active IP Right Cessation
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| EP2298281A1 (en) | 2004-07-12 | 2011-03-23 | Dizlin Medical Design AB | Infusion and injection solution of Levodopa |
| JP2015227341A (en) * | 2004-07-12 | 2015-12-17 | ディズリン・メディカル・デザイン・アクチボラゲットＤｉｚｌｉｎ Ｍｅｄｉｃａｌ Ｄｅｓｉｇｎ Ａｂ | Infusion and injection solution of levodopa |
| AU2005262918B2 (en) * | 2004-07-12 | 2010-12-23 | Dizlin Medical Design Ab | Infusion and injection solution of Levodopa |
| WO2006006929A1 (en) | 2004-07-12 | 2006-01-19 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| JP2013028609A (en) * | 2004-07-12 | 2013-02-07 | Dizlin Medical Design Ab | Levodopa infusion solution and injection solution |
| US8735382B2 (en) | 2004-07-12 | 2014-05-27 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| EA012415B1 (en) * | 2004-07-12 | 2009-10-30 | Дизлин Медикал Дизайн Аб | Infusion and injection solution of levodopa |
| JP2008505966A (en) * | 2004-07-12 | 2008-02-28 | ディズリン・メディカル・デザイン・アクチボラゲット | Infusion and injection of levodopa |
| US20140221489A1 (en) * | 2004-07-12 | 2014-08-07 | Dizlin Medical Design Ab | Infusion and Injection Solution of Levodopa |
| US9248113B2 (en) | 2004-07-12 | 2016-02-02 | Dizlin Medical Design Ab | Infusion and injection solution of Levodopa |
| WO2018224501A1 (en) | 2017-06-05 | 2018-12-13 | Dizlin Pharmaceuticals Ab | Levodopa infusion solution |
| CN110753538A (en) * | 2017-06-05 | 2020-02-04 | 迪兹林制药公司 | Levodopa infusion solutions |
| EP3838263A1 (en) | 2017-06-05 | 2021-06-23 | Dizlin Pharmaceuticals AB | Levodopa infusion solution |
| AU2018280745B2 (en) * | 2017-06-05 | 2023-03-09 | Dizlin Pharmaceuticals Ab | Levodopa infusion solution |
| US11633353B2 (en) | 2017-06-05 | 2023-04-25 | Dizlin Pharmaceuticals Ab | Levodopa infusion solution |
Also Published As
| Publication number | Publication date |
|---|---|
| SE9303787L (en) | 1995-05-18 |
| SE9303787D0 (en) | 1993-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117668T1 (en) | PHARMACEUTICAL RECOMMENDATIONS INCLUDING INSULIN CONTAINED WITH A DICETEPIPERAZINE | |
| KR920019371A (en) | Stabilized Factor Ⅷ Formulations | |
| ES2075468T3 (en) | DRUG SUPPLY VEHICLES SUSPENDED ON A NON-WATER PERFLUORED CARRIER. | |
| CO5190689A1 (en) | TRAMADOL SALTS FORMED BY TRAMADOL AND A SWEETENER AND PHARMACEUTICAL FORMS CONTAINING SALES | |
| CY1116197T1 (en) | LEVENTOPA INJECTION AND INJECTION SOLUTION | |
| ATE333260T1 (en) | A CARTRIDGE AND A MEDICAL DELIVERY SYSTEM THAT ACCOMMODATE SUCH A CARTRIDGE | |
| BR0209198A (en) | Synthesis methods of phenol-containing compounds | |
| ATE157007T1 (en) | 6-CYCLOHEXYL-2'-0-METHYL-ADENOSINE HYDRATE AND USES THEREOF | |
| KR940003564A (en) | Use of C1-inactive agents to prepare medicaments for the prevention and treatment of certain diseases | |
| SE512655C2 (en) | Medication for infusion treatment | |
| Kind et al. | Outpatient intravenous antibiotic therapy: Ten years' experience | |
| Jewell et al. | Heparin and ethyl biscoumacetate in prevention of experimental venous thrombosis | |
| ATE233105T1 (en) | PHARMACEUTICAL PREPARATION FOR INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION OF OCTREOTIDE | |
| KR910002456A (en) | Pharmaceutical composition for the treatment of diabetes | |
| KR910007522A (en) | Stabilized Aqueous Solution of Water-soluble Pentamidine Salts | |
| JP2739482B2 (en) | Method for producing stable calcitonin injection | |
| LV11524A (en) | Use of benzidamine as a treatment for pathological conditions induced by TNF | |
| EA200700968A1 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES MELLITUS TYPE 2 | |
| Wiegman | Tips for avoiding toxicity | |
| Ching et al. | An oral treatment for lead toxicity. | |
| Gray et al. | Chlormethiazole sedation for critically ill patients in renal failure | |
| KR930700138A (en) | Intraocular Surgery | |
| 王家秀 | THE FIRST MONOGRAPH ON SURGERY | |
| Moore et al. | Vascular Lesions in Diabetes | |
| Feigenbaum | Some unusual manifestations of the insulin reaction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |